|
Occulogix, Inc. - Sales Analysis Snapshot
Business Description This Report provides a comprehensive Sales & Margin summary analysis for Occulogix, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.
Occulogix, Inc.. The Group's principal activity is to provide therapeutic treatments for eye diseases, including age-related macular degeneration or AMD. AMD is a chronic, progressive disease of the macular, or the central part of the retina, that results in the loss of central vision, and cannot be corrected by refractive means, such as glasses, contact lenses or laser eye surgery. The Group's major product is the RHEO system, which is designed to improve microcirculation in the eye by filtering high molecular weight proteins and other macromolecules from the patient's plasma. This system is used to perform Rheopheresis, a blood filtration process that selectively removes molecules from plasma. The trademarks of the Group include RHEO Therapy and Rheologix. The major customer of the Group is RHEO Clinic Inc. Currently, the Group generates its revenues only through operations in Canada.
Not the Report you are looking for? Click here for more browsing options.
Layout and Content of a Typical Report
|